预约演示
更新于：2025-05-16
Sotalol Hydrochloride
盐酸索他洛尔
更新于：2025-05-16
概要
基本信息
药物类型 小分子化药 |
别名 索他洛尔、MJ-1999、MJ1999 + [9] |
作用方式 拮抗剂 |
作用机制 β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 (1973-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C12H21ClN2O3S |
InChIKeyVIDRYROWYFWGSY-UHFFFAOYSA-N |
CAS号959-24-0 |
关联
33
项与 盐酸索他洛尔 相关的临床试验ChiCTR2400088934
The prevention effect of Sotalol for post-operative atrial fibrillation after coronary artery bypass grafting: a randomized contrlled trial - Sotalol for POAF after CABG
CTR20241925
盐酸索他洛尔片（80mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
IRCT20231123060154N1
Evaluation of the effect of oral sotalol in comparison with oral metoprolol succinate in prevention of atrial fibrillation in patients after coronary artery bypass graft surgery
100 项与 盐酸索他洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸索他洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸索他洛尔 相关的专利（医药）
登录后查看更多信息
5,362
项与 盐酸索他洛尔 相关的文献（医药）2025-12-31SCANDINAVIAN CARDIOVASCULAR JOURNAL
The use of antiarrhythmic drugs for atrial fibrillation in Finland 2007–2018
Article
作者: Siponen, Rasmus ; Marjamaa, Annukka ; Lehto, Mika ; Hartikainen, Juha ; Putaala, Jukka ; Teppo, Konsta ; Aro, Aapo ; Airaksinen, Juhani ; Mustonen, Pirjo ; Salmela, Birgitta ; Haukka, Jari ; Virrankorpi, Janne ; Linna, Miika ; Lappalainen, Antti ; Halminen, Olli
BACKGROUND:
Patients with atrial fibrillation (AF) are often treated with antiarrhythmic drugs (AADs) to maintain sinus rhythm and with heart rate-lowering drugs to achieve the optimal rate control. In this study, we investigated trends in the use of AADs and rate control drugs in Finnish patients with AF.
METHODS AND RESULTS:
The Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study is a nationwide study including all patients with AF in Finland from 2007 to 2018. The number of AAD purchases and the proportions of all prevalent AF patients in a certain year of interest were calculated. In total, 391030 AF patients were identified between 2007 and 2018, and 39,816 (10.2%) of them had purchased either class I or III AADs. The proportion of patients using classes I and III AADs decreased from 8.6% to 6.3%. Flecainide and amiodarone were the most often used AADs. The use of flecainide and amiodarone decreased from 4.9% to 3.9% and 1.9% to 1.5%, respectively. The proportion of patients on beta-blockers remained stable at 75%. Dronedarone became available in 2011 when it also was the most used (0.8% of patients), but the use decreased thereafter. The use of sotalol and digoxin decreased from 1.5% to 0.6% and 24.6% to 11.0% over the study period.
CONCLUSION:
The number of AAD purchases increased alongside with the increasing prevalence of AF, whereas the proportion of AF patients on classes I and III AADs and digoxin decreased between 2007 and 2018. Flecainide remained the most used AAD followed by amiodarone.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-06-01Water Resources and Industry
Monitoring pharmaceuticals and personal care products to assess water quality changes and pollution sources in a drinking water reservoir catchment
作者: Witkowski, Andrzej J. ; Slosarczyk, Kinga ; Wolny, Filip
This research aimed to identify sources of pharmaceuticals and personal care products (PPCPs) in the Kozlowa Gora catchment, southern Poland, and assess their temporal and spatial variability.PPCP monitoring was conducted from 2020 to 2022.Samples were taken from the Brynica River and other streams.Groundwater and the effluent from the wastewater treatment plant (WWTP) were also sampled.The monitoring screened 109 PPCPs using the LC-MS/MS method.N,N-Diethyl-meta-toluamide (DEET), metformin, 1-H-benzotriazole, perfluorooctane sulfonic acid (PFOS), carbamazepine, and 4(5)-methyl-1-H-benzotriazole were the most frequently detected substances.The highest total PPCP concentrations in surface waters reached 30790 ng/L, with up to 53 compounds detected at one point.Results indicated temporal and spatial variability, with higher concentrations and more PPCPs during winter periods and increased contamination downstream from the WWTP.DEET was the only contaminant consistently found in the shallow aquifer discharged into the Brynica, however groundwater impact on the river ′s water quality is negligible.The study confirmed the WWTP as the primary source of PPCPs, with the number of detected substances in effluent samples amounting to 65 and their total concentrations reaching 148265 ng/L.Addnl. sources included the airport, uncontrolled/illegal domestic sewage discharges, and human activities in forested areas.This study was the first in Poland to implement a PPCP monitoring approach in a drinking water reservoir catchment area using multiple monitoring points and sampling campaigns.The results revealed the constant presence of PPCPs in a moderately urbanised catchment area, highlighting the importance of regular monitoring to understand PPCP migration in the environment.
100 项与 盐酸索他洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 室性心动过速 | 日本 | 1998-09-30 | |
| 心室颤动 | 日本 | 1998-09-30 | |
| 心房颤动 | 美国 | 1992-10-30 | |
| 心房扑动 | 美国 | 1992-10-30 | |
| 室性心律失常 | 美国 | 1992-10-30 | |
| 心律失常 | - | 1973-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 163 | Sotalol 80 mg | 膚製顧壓糧觸鹹鑰繭積(膚蓋構壓觸衊膚鏇鏇廠) = 窪願鏇淵醖窪鑰衊窪蓋 製製鏇遞襯製淵壓簾遞 (艱範齋鑰遞範繭範壓網 ) | 积极 | 2025-04-09 | ||
Sotalol 120 mg | 膚製顧壓糧觸鹹鑰繭積(膚蓋構壓觸衊膚鏇鏇廠) = 構網築積鑰積壓鏇鹽淵 製製鏇遞襯製淵壓簾遞 (艱範齋鑰遞範繭範壓網 ) | ||||||
N/A | - | 膚壓網網廠構鹽鹽憲築(醖鑰築襯齋餘範廠壓齋) = 膚願齋觸鹽鹽觸廠鏇夢 襯窪衊願選艱鬱範衊鬱 (繭獵憲築糧廠願鬱範齋 ) 更多 | - | 2024-04-09 | |||
膚壓網網廠構鹽鹽憲築(醖鑰築襯齋餘範廠壓齋) = 醖遞鑰齋衊艱願築鬱製 襯窪衊願選艱鬱範衊鬱 (繭獵憲築糧廠願鬱範齋 ) 更多 | |||||||
N/A | - | - | Patients taking antiarrhythmic drugs | 製齋範襯鬱醖衊範齋糧(鹹窪製齋製鬱廠範網繭) = 積鏇醖夢鬱鹽顧遞鬱艱 鬱餘願獵製艱糧選衊鹽 (鹹蓋製鹽鏇構廠構製壓 ) | - | 2024-04-08 | |
Patients not taking antiarrhythmic drugs | 製齋範襯鬱醖衊範齋糧(鹹窪製齋製鬱廠範網繭) = 構鑰鏇齋繭製築蓋壓範 鬱餘願獵製艱糧選衊鹽 (鹹蓋製鹽鏇構廠構製壓 ) | ||||||
N/A | - | Sotalol-treated patients | 窪範憲襯築衊憲鹽顧夢(壓蓋壓壓積鹽顧顧壓夢) = 鬱襯願積衊積蓋選艱鹹 蓋簾餘糧鹽繭窪淵積構 (膚餘窪齋觸衊網糧憲廠 ) | - | 2023-04-18 | ||
临床1期 | - | 990 | Sotalol 80mg | 鏇鬱簾簾觸鹹範憲憲淵(糧醖製積鹹選窪繭壓齋) = 鏇鏇鬱壓顧選蓋窪餘憲 壓壓選餘鏇夢衊淵積蓋 (選製衊範製膚顧夢願襯 ) | - | 2017-01-01 | |
N/A | 27 | Biosense Webster's NAVI-STAR Thermo-Cool (Catheter Ablation) | 廠鏇遞艱鑰顧憲遞壓選 = 醖壓壓鬱鬱窪齋選鹹窪 壓衊艱築餘襯遞衊餘繭 (鑰醖獵壓範鬱鑰衊醖觸, 鑰築壓範憲築衊艱選選 ~ 觸糧繭醖繭糧繭遞蓋鹹) 更多 | - | 2014-09-25 | ||
(Antiarrhythmic Medication) | 廠鏇遞艱鑰顧憲遞壓選 = 餘衊蓋繭鬱醖醖觸鏇壓 壓衊艱築餘襯遞衊餘繭 (鑰醖獵壓範鬱鑰衊醖觸, 齋醖製餘顧鹽壓壓夢糧 ~ 繭選簾遞憲窪獵顧鬱範) 更多 | ||||||
N/A | 110 | Radiofrequency catheter ablation (AAD:NO) | 遞齋壓窪廠糧網鬱範願 = 餘襯蓋範選餘窪鑰鏇範 網顧鏇膚繭餘築範觸獵 (壓蓋鹽鑰窪獵觸淵遞鑰, 鬱網構願齋鬱製壓願壓 ~ 願夢觸鹽蓋築鹽遞艱鬱) 更多 | - | 2013-03-07 | ||
(AAD:YES) | 遞齋壓窪廠糧網鬱範願 = 積餘壓築窪膚憲範積構 網顧鏇膚繭餘築範觸獵 (壓蓋鹽鑰窪獵觸淵遞鑰, 繭壓膚製繭廠鏇艱鬱簾 ~ 範夢窪觸製網選簾鹽鹽) 更多 | ||||||
N/A | 60 | Ablation Therapy | 襯壓鹽夢餘齋鬱遞夢艱 = 淵淵艱範繭簾遞餘積艱 獵遞齋範遞醖構積餘製 (簾膚膚鑰衊壓觸襯觸襯, 襯憲窪膚鬱壓遞艱範遞 ~ 窪築醖夢遞範鑰繭廠醖) 更多 | - | 2013-01-04 | ||
临床4期 | 412 | Beta-blocker alone | 觸衊蓋艱鬱窪鹽夢窪憲(鹹憲網選願築構築構鏇): HR = 0.61 (95% CI, 0.37 ~ 1.01), P-Value = 0.055 更多 | 积极 | 2006-01-11 | ||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用